Carmat artificial heart patient in satisfactory condition -hospital

PARIS Wed Feb 19, 2014 1:45am IST

Chairman of Carmat Jean-Claude Cadudal (L), Professor Christian Latremouille (C) of the department of cardiovascular surgery and transplant of organs at the Georges Pompidou European Hospital and French Social Affairs and Health Minister Marisol Touraine attend a news conference at the Georges Pompidou European Hospital in Paris, December 21, 2013. REUTERS/Benoit Tessier/Files

Chairman of Carmat Jean-Claude Cadudal (L), Professor Christian Latremouille (C) of the department of cardiovascular surgery and transplant of organs at the Georges Pompidou European Hospital and French Social Affairs and Health Minister Marisol Touraine attend a news conference at the Georges Pompidou European Hospital in Paris, December 21, 2013.

Credit: Reuters/Benoit Tessier/Files

Related Topics

Stocks

   

PARIS (Reuters) - A patient with terminal heart failure is in "satisfactory condition" two months after becoming the first person to be fitted with Carmat's (ALCAR.PA) artificial heart which is designed to beat for several years, his hospital said.

The 76-year-old man is eating normally, no longer needs constant respiratory assistance and is able to walk a little further every day thanks to physical therapy, the Georges Pompidou European Hospital in Paris said in a statement on Tuesday.

"The Carmat bioprosthesis continues to function satisfactorily, without any anti-clotting treatment since January 10," said the hospital, where the implant surgery was performed on December 18 and where the patient is being treated.

It praised the patient's "exemplary courage, sense of humour and family support" for playing a role in his recovery.

Heart-assistance devices have been used for decades as a temporary solution for patients awaiting transplants, but Carmat's product is designed to replace the real heart over the long term, mimicking nature using biological materials and sensors.

It aims to extend life for thousands of patients who die each year while awaiting a donor, while reducing the side-effects that can be associated with transplants, such as blood clots and rejection.

Three more patients in France are due to be fitted with Carmat's device. The people selected in this first series of clinical studies suffer from terminal heart failure - when the sick heart can no longer pump enough blood to sustain the body - and would otherwise have only a few days or weeks to live.

Success will be judged on whether the patients survive with the implant for at least a month. If deemed safe, the device will then be fitted into about 20 lower-risk patients.

A spokeswoman for Carmat declined to say when the other three patients in the first round of tests would be fitted with its artificial heart.

The company estimates around 100,000 patients in the United States and Europe could benefit from its artificial heart, a market worth more than 16 billion euros

Chief Executive Marcello Conviti told Reuters in November that Carmat hoped to finish human trials of the heart by the end of 2014 and to obtain approval to market them in the European Union by early 2015.

Among its competitors for artificial heart implants are privately-held SynCardia Systems and Abiomed (ABMD.O), both of the United States.

(Reporting by Natalie Huet; Editing by Pravin Char)

FILED UNDER:

Tech Wrap

Reuters Showcase

Stake Sale

Stake Sale

Strong demand for Coal India boosts privatisation drive.  Full Article 

Pharma Deal

Pharma Deal

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy  Full Article 

SpiceJet Bailout

SpiceJet Bailout

SpiceJet board approves up to $243 mln share sale plan  Full Article 

AirAsia Jet Crash

AirAsia Jet Crash

AirAsia captain left seat before jet lost control - sources  Full Article 

India Art Fair

India Art Fair

Art fair turns India's capital into art hub.  Full Article 

Romney Opts Out

Romney Opts Out

Republican Romney opts out of 2016 run for president.  Full Article 

Movie Review

Movie Review

"Rahasya" is an ode to Agatha Christie.  Full Article 

Safety Concerns

Safety Concerns

Aviation leaders seek new safety mandate after deadly 2014.  Full Article 

Movie Review: Hawaizaada

Movie Review: Hawaizaada

Movie Review: Hawaizaada  Full Article | Related Story 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage